PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 9-29-03 Filing Date INFORMATION DISCLOSURE First Named Inventor Bobrowski, Paul J. STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) Examiner Name Attorney Docket Number PHMC0745-021 Sheet 1

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 5156847		Winter et al.	
SONE		^{US-} 5156847		Lewis et al.	
SBNB		^{US-} 5211944		Tempesta	
SAME		^{US-} 5494661		Tempesta	
		US-			
		US-	 		
		US-			
		US-			
		US-			
		US-			
		US-	1		
		US-			
		US-	 		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Π	
			MM-DD-YYYY			1	
	ļ		·				
	ļ					L	
						Ľ	

	· · · · · · · · · · · · · · · · · · ·		
Examiner	CAMAR / C 114	Date	0(
Signature	SB McCorneh-Ewoldt	Considered	3-3-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC

Substitute for form 1449/PTO		Complete if Known			
333333				Application Numb r	
INF	ORMATION	DIS	CLOSURE	Filing Date	9-29-03
(Use as many sheets as necessary)			PPLICANT	First Named Inventor	Bobrowski, Paul J.
				Art Unit	
			iecessary)	Examiner Name	
Sheet	2	of	3	Attorney Docket Number	PHMC0745-021

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
SB ME		RINALDO MARINI BETTOLO & M. LUISA SCARPATI, Alkaloids of Croton Draconoides, Article, 1 page, 1979	
		GEORGIA PERSINOS PERDUE ET AL., South American Plants II: Taspine Isolation and Anti-Inflammatory Activity, J. of Pharmaceutical Sciences, V68 No.1 Jan 1979, pg. 124 U.S.	
		ABRAHAM J. VAISBERG et al., Taspine is the Cicatrizant Principle in Sangre de Grado Extracted from Croton Lechleri, Plant Medica 55 (1989), pgs 140-143, U.S.	
		LUC PIETERS ET AL., Isolation of a Dihydrobenzofuran Ligan from South American Dragon's Blood (Croton spp.) as an Inhibitor of Cell Proliferation, 1993, U.S.	
		J. DAVID PHILLIPSON, A Matter of Some Sensitivity, PhytoChemistry, Vol.38 No.6 pp1319-1343, 1995 U.S.	
		MARK J.S. MILLER ET AL., Inhibition of Neurogenic Inflammation by the Amazonian Herbal Medicine Sangre de Grado, J. Invest Dermatology 117:725-730, 2001, U.S.	
		S.E. GABRIEL ET AL., A Novel Plant-Derived Inhibitor of cAMP-mediated fluid and Chloride Secretion, Am. J. Physiol. 267, G58-63, 1999, U.S.	
,		MARK HOLODNIY, M.D. ET AL., A Double Blind Randomized, Placebo-Controlled Phase II Study to Assess the Safety and Efficacy Am. J. Gastroenterology, Vol94,No.11, 1999, U.S.	
		BEATE ILLEK ET AL., A novel extract from the bark latex of Croton lechleri inhibits cAMP-mediated chloride secretion, Dec. 2000, U.S.	
V		MARK J.S. MILLER ET AL., Treatment of gastric ulcers and diarrhea with the Amazonian herbal medicine, Am J Phisiol Gastrointes Liver Physiol 279: G192-200, 2000	

Examiner Signature	S.B. Mc Commithe worldt	Date Considered	5-5-05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Compl te if Known Substitute for form 1449/PTO Application Numb r INFORMATION DISCLOSURE **Filing Dat** 9-29-03 STATEMENT BY APPLICANT **First Named Inventor** Bobrowski, Paul J. Art Unit (Use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number 3 3 PHMC0745-021

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
821V6		MANUEL SANDOVAL, Sangre de grado Croton palanostigma induces apoptosis in human gastrointestinal cancer cells, J. Ethno-Pharmacology, 80, pp. 121-129, 2002, U.S.	
STANG		Zheng-Ping Chen et al., Studies on the Anti-Tumour, Anti-Bacterial, and Wound-Healing Properties of Dragon's Blood, Planta Med. 60 (1994) 541-545	
		·	

Examiner	Campo 1 Can	Date	5505
Signature	S.B. McCornich-Ewalst	Considered	5-5-01

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.